6 647

Cited 39 times in

Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma

DC Field Value Language
dc.contributor.author김주항-
dc.contributor.author김현정-
dc.contributor.author김혜련-
dc.contributor.author배미경-
dc.contributor.author심효섭-
dc.contributor.author이진구-
dc.contributor.author이창영-
dc.contributor.author임선민-
dc.contributor.author정경영-
dc.contributor.author정지예-
dc.contributor.author조병철-
dc.contributor.author김대준-
dc.contributor.author김민환-
dc.contributor.author김은영-
dc.contributor.author박지수-
dc.date.accessioned2015-01-06T16:38:11Z-
dc.date.available2015-01-06T16:38:11Z-
dc.date.issued2014-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98474-
dc.description.abstractOBJECTIVES: The aim of this study is to evaluate the prevalence and prognostic significance of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangement in never-smokers with surgically resected lung adenocarcinoma. METHODS: We retrospectively analyzed 162 consecutive never-smokers who underwent curative resection for stage IB to IIIA lung adenocarcinoma at a single institution. We concurrently analyzed mutations in the epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) genes, and investigated ALK rearrangements by fluorescence in situ hybridization assay. ROS1 rearrangement was also determined in all triple (EGFR/KRAS/ALK)-negative tumors. RESULTS: Of 162 never smokers with lung adenocarcinoma, 14 (8.6%) and 5 (3.1%) had ALK and ROS1 rearrangements, respectively. Nineteen of the 74 (25.7%) EGFR and KRAS mutation-negative patients were fusion-positive (ALK or ROS1 fusion). Fusion-positive patients tended to have shorter median disease-free survival (DFS) than fusion-negative patients (28.0 vs. 33.9 months; p=0.128). In multivariate analysis, fusion-positive patients had significantly poorer DFS than fusion-negative patients after adjustment for age, sex, T stage, N stage, and adjuvant chemotherapy use (p=0.022; hazard ratio, 2.11; 95% confidence interval, 1.19-4.30). The first recurrence sites were not significantly different between fusion-positive and fusion-negative patients in this study. CONCLUSION: This study shows significantly poorer DFS of ALK or ROS1 fusion-positive lung adenocarcinoma in never-smokers after curative surgery.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/diagnosis*-
dc.subject.MESHAdenocarcinoma/genetics-
dc.subject.MESHAdenocarcinoma/mortality*-
dc.subject.MESHDNA Mutational Analysis-
dc.subject.MESHGene Rearrangement/genetics-
dc.subject.MESHLung Neoplasms/diagnosis*-
dc.subject.MESHLung Neoplasms/genetics-
dc.subject.MESHLung Neoplasms/mortality-
dc.subject.MESHMutation/genetics-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPneumonectomy-
dc.subject.MESHProtein-Tyrosine Kinases/genetics*-
dc.subject.MESHProto-Oncogene Proteins/genetics*-
dc.subject.MESHProto-Oncogene Proteins p21(ras)-
dc.subject.MESHReceptor Protein-Tyrosine Kinases/genetics*-
dc.subject.MESHReceptor, Epidermal Growth Factor/genetics-
dc.subject.MESHRecurrence-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSmoking-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHras Proteins/genetics-
dc.titleClinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic & Cardiovascular Surgery (흉부외과학)-
dc.contributor.googleauthorMin Hwan Kim-
dc.contributor.googleauthorHyo Sup Shim-
dc.contributor.googleauthorDae Ryong Kang-
dc.contributor.googleauthorJi Ye Jung-
dc.contributor.googleauthorChang Young Lee-
dc.contributor.googleauthorDae Joon Kim-
dc.contributor.googleauthorJin Gu Lee-
dc.contributor.googleauthorMi Kyung Bae-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorEun Young Kim-
dc.contributor.googleauthorJi Soo Park-
dc.contributor.googleauthorKyung Young Chung-
dc.contributor.googleauthorHyun-Jung Kim-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.1016/j.lungcan.2014.01.003-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00945-
dc.contributor.localIdA01166-
dc.contributor.localIdA01792-
dc.contributor.localIdA02219-
dc.contributor.localIdA03225-
dc.contributor.localIdA03245-
dc.contributor.localIdA03369-
dc.contributor.localIdA03571-
dc.contributor.localIdA03735-
dc.contributor.localIdA03822-
dc.contributor.localIdA00368-
dc.contributor.localIdA00482-
dc.contributor.localIdA00811-
dc.contributor.localIdA01130-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid24462463-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500214000063-
dc.subject.keywordAnaplastic lymphoma kinase-
dc.subject.keywordC-ros oncogene 1-
dc.subject.keywordLung adenocarcinoma-
dc.subject.keywordNever-smokers-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Hyun Jeong-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNameBae, Mi Kyung-
dc.contributor.alternativeNameShim, Hyo Sup-
dc.contributor.alternativeNameLee, Jin Gu-
dc.contributor.alternativeNameLee, Chang Young-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.alternativeNameChung, Kyung Young-
dc.contributor.alternativeNameJung, Ji Ye-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.alternativeNameKim, Min Hwan-
dc.contributor.alternativeNameKim, Eun Young-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorBae, Mi Kyung-
dc.contributor.affiliatedAuthorShim, Hyo Sup-
dc.contributor.affiliatedAuthorLee, Jin Gu-
dc.contributor.affiliatedAuthorLee, Chang Young-
dc.contributor.affiliatedAuthorLim, Sun Min-
dc.contributor.affiliatedAuthorChung, Kyung Young-
dc.contributor.affiliatedAuthorJung, Ji Ye-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorKim, Dae Joon-
dc.contributor.affiliatedAuthorKim, Min Hwan-
dc.contributor.affiliatedAuthorKim, Eun Young-
dc.contributor.affiliatedAuthorKim, Hyun Jeong-
dc.rights.accessRightsfree-
dc.citation.volume83-
dc.citation.number3-
dc.citation.startPage389-
dc.citation.endPage395-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.83(3) : 389-395, 2014-
dc.identifier.rimsid57612-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.